Dynamics of complement activation in aHUS and how to monitor eculizumab therapy by Marina Noris, Miriam Galbusera, Sara Gastoldi, Paolo Macor, Federica.

Slides:



Advertisements
Similar presentations
Volume 70, Issue 7, Pages (October 2006)
Advertisements

Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody– associated vasculitis  Shen-Ju Gou, Jun Yuan, Min Chen, Feng Yu,
Volume 125, Issue 1, Pages (July 2003)
Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models  D.H. Sweet, S.A. Eraly,
IFNα-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity.
Volume 136, Issue 2, Pages e5 (February 2009)
by Kazutaka Hayashida, William C. Parks, and Pyong Woo Park
Hydrocortisone reduced in vivo, inflammation-induced slow rolling of leukocytes and their extravasation into human conjunctiva by Juha Kirveskari, Maaret.
Aliskiren inhibits renin-mediated complement activation
Volume 69, Issue 3, Pages (February 2006)
Volume 125, Issue 1, Pages (July 2003)
Volume 88, Issue 6, Pages (December 2015)
The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated.
Rearranged Ig Heavy Chain DNA Is Detectable in Cell-Free Blood Samples of Patients With B-Cell Neoplasia by N. Frickhofen, E. Müller, M. Sandherr, T. Binder,
by Leila M. Lopes Bezerra, and Scott G. Filler
Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling  Yu-Juei Hsu, MD, PhD, Shih-Che Hsu,
Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia by Teresa Padró, Sandra Ruiz, Ralf Bieker, Horst Bürger, Martin Steins,
Daniel K. Podolsky, Guido Gerken, Annette Eyking, Elke Cario 
C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function by Fleur Bossi,
Anti–factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome by Mihály Józsi, Stefanie Strobel, Hans-Martin.
Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3.
Sanjeev Sethi, Carla M. Nester, Richard J.H. Smith 
Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,
Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and.
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression by Rosalba Salcedo, Maria Lourdes.
Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells by Sergey Krysov, Samantha Dias, Alex Paterson, C.
Hyperphosphatemia induces protective autophagy in endothelial cells through the inhibition of Akt/mTOR signaling  Yu-Juei Hsu, MD, PhD, Shih-Che Hsu,
by Dongmei Song, Xiaobing Ye, Honglei Xu, and Shu Fang Liu
Volume 75, Issue 11, Pages (June 2009)
Circulating complement activation in patients with anti-neutrophil cytoplasmic antibody– associated vasculitis  Shen-Ju Gou, Jun Yuan, Min Chen, Feng Yu,
Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic.
Volume 72, Issue 6, Pages (September 2007)
Volume 15, Issue 1, Pages (January 2007)
Volume 90, Issue 1, Pages (July 2016)
Volume 68, Issue 6, Pages (December 2005)
Structural and Functional Characterization of Factor H Mutations Associated with Atypical Hemolytic Uremic Syndrome  Pilar Sánchez-Corral, David Pérez-Caballero,
Volume 132, Issue 4, Pages (April 2007)
Volume 65, Issue 3, Pages (March 2004)
Volume 62, Issue 2, Pages (August 2002)
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia by Shahrzad Jalali, Tammy Price-Troska, Jonas Paludo, Jose Villasboas, Hyo-Jin.
Zihua Zeng, Ching-Hsuan Tung, Youli Zu 
Enhancing functional platelet release in vivo from in vitro–grown megakaryocytes using small molecule inhibitors by Danuta Jarocha, Karen K. Vo, Randolph.
Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways  Youhua Liu, Krupa Rajur, Evelyn Tolbert,
Abnormally Differentiating Keratinocytes in the Epidermis of Systemic Sclerosis Patients Show Enhanced Secretion of CCN2 and S100A9  Joanna Nikitorowicz-Buniak,
Inter-α inhibitor proteins maintain neutrophils in a resting state by regulating shape and reducing ROS production by Soe Soe Htwe, Hidenori Wake, Keyue.
Abnormally Differentiating Keratinocytes in the Epidermis of Systemic Sclerosis Patients Show Enhanced Secretion of CCN2 and S100A9  Joanna Nikitorowicz-Buniak,
Volume 80, Issue 4, Pages (August 2011)
Volume 78, Issue 2, Pages (July 2010)
Volume 57, Issue 1, Pages (January 2000)
Volume 61, Issue 3, Pages (March 2002)
Organic anion and cation transporter expression and function during embryonic kidney development and in organ culture models  D.H. Sweet, S.A. Eraly,
Response of Psoriasis to Interleukin-10 is Associated with Suppression of Cutaneous Type 1 Inflammation, Downregulation of the Epidermal Interleukin-8/CXCR2.
Glomerular injury is exacerbated in diabetic integrin α1-null mice
by Geling Li, Emily Waite, and Julie Wolfson
Volume 75, Issue 10, Pages (May 2009)
Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?  Marina Noris, PhD, Piero Ruggenenti, MD,
Volume 72, Issue 3, Pages (August 2007)
by Defne Bayik, Debra Tross, Lydia A
The oncogenic membrane protein LMP1 sequesters TRAF3 in B-cell lymphoma cells to produce functional TRAF3 deficiency by Pradeep Bangalore-Prakash, Laura.
Potentiation of complement regulator factor H protects human endothelial cells from complement attack in aHUS sera by Richard B. Pouw, Mieke C. Brouwer,
Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies by Nadine Müller-Calleja, Svenja.
Volume 80, Issue 2, Pages (July 2011)
Significant pathological changes and activation of Nrf2 pathway in the glomeruli of human diabetic nephropathy patients. Significant pathological changes.
Effect of age and biopsy site on extracellular matrix mRNA and protein levels in human kidney biopsies  Michael Eikmans, Hans J. Baelde, Emile De Heer,
Volume 78, Issue 3, Pages (August 2010)
Eculizumab Therapy in Children with Severe Hematopoietic Stem Cell Transplantation– Associated Thrombotic Microangiopathy  Sonata Jodele, Tsuyoshi Fukuda,
Volume 16, Issue 10, Pages (October 2008)
Volume 57, Issue 1, Pages (January 2000)
EGF induces HPSE nucleolar localization in human BMBC cells.
Presentation transcript:

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy by Marina Noris, Miriam Galbusera, Sara Gastoldi, Paolo Macor, Federica Banterla, Elena Bresin, Claudio Tripodo, Serena Bettoni, Roberta Donadelli, Elisabetta Valoti, Francesco Tedesco, Alessandro Amore, Rosanna Coppo, Piero Ruggenenti, Eliana Gotti, and Giuseppe Remuzzi Blood Volume 124(11):1715-1726 September 11, 2014 ©2014 by American Society of Hematology

Immunohistochemical analysis of C3 and C9 (C5b-9) staining in kidney biopsy specimens from aHUS patients. Immunohistochemical analysis of C3 and C9 (C5b-9) staining in kidney biopsy specimens from aHUS patients. Representative results are shown. (A) C3 deposits with main endothelial localization in a glomerulus from a patient with a CFI mutation and normal SC5b-9 plasma levels. (B) C9 staining restricted to hilar area in a glomerulus from a patient with a C3 mutation. (C) Diffuse C9 deposits in 2 glomeruli with marked ischemic injury from a patient with CFH mutation and increased SC5b-9 levels. (D) C9 deposits in glomeruli from a patient without mutations/anti-CFH antibodies. (E-F) endothelial C3 staining in arterioles from patients with CFH (E) and CFI (F) mutations. (G) Subendothelial localization of C9 staining in an arteriole from a patient with a CFH mutation and normal SC5b-9 level. (H) Control section (healthy portion of nephrectomy for cancer, C9 staining). Original magnification ×400, counterstaining with hematoxylin. Marina Noris et al. Blood 2014;124:1715-1726 ©2014 by American Society of Hematology

aHUS serum induces C3 and C5b-9 deposition on microvascular endothelial cells (HMEC-1). aHUS serum induces C3 and C5b-9 deposition on microvascular endothelial cells (HMEC-1). (A-B) Endothelial surface area covered by C3 (A) or C5b-9 (B) staining after incubation of unstimulated (resting) or ADP-activated HMEC-1 for 4 hr with serum (diluted 1:2 in test medium) from healthy subjects (Ctr; n = 4) or from aHUS patients (C3: n = 3, 1 with CFH mutation, 1 with anti-CFH antibodies, and 1 without identified mutations/anti-CFH antibodies; C5b-9: n = 7, 3 with CFH mutation, 1 with anti-CFH antibodies, and 3 without identified mutations/anti-CFH antibodies) studied both during the acute phase of the disease (Acute) and at remission (Rem) or from 7 aHUS patients studied in the acute phase only (panel B, C5b-9, acute only, all without identified mutations/anti-CFH antibodies). Data are mean ± standard error (SE). ^P < .01 vs control resting; °°P < .01, °°°P < .05 vs control ADP-activated; &P < .001, &&P < .01, &&&P < .05 vs remission resting. (C,E) Endothelial surface area covered by C3 (C) or C5b-9 (E) staining after incubation of ADP-activated HMEC-1 for 4 hr with serum from aHUS patients studied in remission (C3: n = 25, CFH mutations: n = 10; CFI mutations: n = 4; C3 mutations: n = 3; CFB mutation: n = 1; anti-CFH antibodies: n = 2; without identified mutations/anti-CFH antibodies: n = 5 ; C5b-9: n = 29, CFH mutations or CFHR1/CFH hybrid gene: n = 12; anti-CFH antibodies: n = 2; CFI mutations: n = 4; C3 mutations: n = 3; CFB mutation: n = 1; without identified mutations/anti-CFH antibodies: n = 7), in the presence or not of the complement inhibitor sCR1 (150 μg/mL). Range of deposits induced by control serum (mean ± SE): dotted horizontal areas. (D,F) Representative confocal microscopy images of C3 (D, in green) or C5b-9 (F, in green) staining of ADP-activated HMEC-1 exposed to serum from an healthy subject (Ctr) or an aHUS patient in remission (aHUS) (original magnification ×400). Additional images are shown in supplemental Figure 11. Data are mean ± SE. °P < .001, °°°P < .05 vs control serum; *P < .001, **P < .01 vs aHUS serum without sCR1. Both C3 and C5b-9 deposits were prevented by addition of sCR1 (an inhibitor of all the 3 complement pathways) to patient serum, indicating that the staining was specifically related to complement activation products. mut, mutation. Marina Noris et al. Blood 2014;124:1715-1726 ©2014 by American Society of Hematology

Effect of complement inhibitors on aHUS serum-induced C3 and C5b-9 deposition on ADP-activated HMEC-1. Effect of complement inhibitors on aHUS serum-induced C3 and C5b-9 deposition on ADP-activated HMEC-1. (A-B) Effect of selective inhibitors of the alternative pathway of complement, an anti-CFB antibody (anti-CFB, 150 μg/mL), the CR2-FH fusion protein (CR2-FH, 150 μg/mL and 300 μg/mL), and a CFH concentrate from human plasma (CFH conc, at levels comparable to those of normal human serum, 230 μg/mL) on C3 deposition induced on ADP-activated HMEC-1 by serum from 3 patients with aHUS and CFH mutations studied in remission in 3 independent experiments. (C) Effect of terminal complement pathway inhibitors, an anti-C5 minibody (anti-C5, 135 μg/mL), or an anti-C7 goat polyclonal antibody (anti-C7, 350 μg/mL) or eculizumab (Ecu, 150 μg/ml) on C5b-9 deposition induced on ADP-activated HMEC-1 by serum of patients with aHUS studied in remission. Data are from 3 different experiments in 3 patients (CFH mutations, n = 2; C3 mutation, n = 1) and 3 controls. (D) Effect of 3 doses of eculizumab (Ecu; 100, 50, or 25 μg/mL) on C5b-9 deposition on ADP-activated HMEC-1 induced by serum of patients with aHUS studied in the acute phase before any treatment. Data are from 3 different experiments in 3 patients (without mutations or anti-CFH antibodies) and 3 controls. Data are mean ± SE. °P < .001, °°P < .01, °°°P < .05 vs control serum; *P < .001, **P < .01, ***P < .05 vs aHUS serum untreated. Control range: dotted horizontal areas. ctr, control. Marina Noris et al. Blood 2014;124:1715-1726 ©2014 by American Society of Hematology

Serum from healthy carriers of complement gene mutations induces C3 and C5b-9 deposition on ADP-activated microvascular endothelial cells (HMEC-1). Serum from healthy carriers of complement gene mutations induces C3 and C5b-9 deposition on ADP-activated microvascular endothelial cells (HMEC-1). (A-B) Endothelial surface area covered by C3 (A) or C5b-9 (B) staining after incubation of ADP-activated HMEC-1 for 4 hr with serum (diluted 1:2 in test medium) from aHUS patients (C3 deposits: n = 6, 4 with CFH mutations, 1 with C3 mutation, and 1 with CFI mutation; C5b-9 deposits: n = 7, 4 with CFH mutations, 1 with C3 mutation, 1 with CFI mutation, and 1 with CFHR1/CFH hybrid gene) or from their healthy relatives carrying the same mutations (C3 deposits: n = 5, 3 with CFH mutation, 1 with C3 mutation, and 1 with CFI mutation; C5b-9 deposits: n = 6, 3 with CFH mutation, 1 with C3 mutation, 1 with CFI mutation, and 1 with CFHR1/CFH hybrid gene) in the presence or not of the complement inhibitor sCR1 (150 μg/mL) or from 7 healthy relatives without mutations (C5b-9 deposits). Control serum range: dotted horizontal areas. Data are mean ± SE. °P < .001, °°P < .01, vs control serum; *P < .001, **P < .01 vs aHUS patients without sCR1; §P < .001 vs mutation carriers without sCR1; #P < .01 vs carrier; &P < .001, &&P < .01 vs no carrier. (C) Data of plasma SC5b-9 levels and serum-induced C3 and C5b-9 deposition on ADP-activated HMEC-1 in unaffected relatives carrying complement gene mutations (healthy mutation carrier, n = 7) and unaffected relatives without mutations (only C5b-9, healthy no carrier, n = 7). °Limits of normal ranges (as defined in supplemental “Methods”). *P < .05 vs control serum (statistical comparisons were made for each relative by comparing deposits in pixel2 recorded in 15 fields analyzed for the relative and for the corresponding control run in parallel, as detailed in supplemental “Methods”). £: Serum-induced C3 or C5b-9 deposits on ADP-activated HMEC-1. mut, mutation; n.a., not available; n.d., not done. Marina Noris et al. Blood 2014;124:1715-1726 ©2014 by American Society of Hematology

Effect of eculizumab on clinical and complement parameters in case 5. Effect of eculizumab on clinical and complement parameters in case 5. Treatments, platelet count, plasma SC5b-9 levels, and serum-induced complement deposition on ADP-activated HMEC-1 (by calculating HMEC-1 area covered by C5b-9 staining in pixel2) after incubation (4 hr) with serum (diluted 1:2 with test medium) from case 5 taken immediately pretransplant before eculizumab treatment (pre-Ecu), at 15 months posttransplant after eculizumab treatment (post-Ecu, 300 or 600 mg), and 21 months posttransplant after eculizumab treatment (post-Ecu, 600 mg). Green arrow indicates eculizumab prophylaxis for kidney transplant. Black arrow indicates the time of kidney transplant. Red arrows indicate times of sampling for plasma SC5b-9 and serum-induced ex vivo complement deposits. Data are mean ± SE of 15 fields examined for each sample. The horizontal rectangle shows range of endothelial C5b-9 deposits with control sera (mean ± SE). °P < .001, °°°P < .05 vs control serum; #P < .01 vs case 5 pre-Ecu; xxxP < .05 vs case 5, 8 days post-Ecu 300 mg. Marina Noris et al. Blood 2014;124:1715-1726 ©2014 by American Society of Hematology

Effect of eculizumab on clinical and complement parameters in case 7. Effect of eculizumab on clinical and complement parameters in case 7. Treatments, platelet count, plasma SC5b-9 levels, and complement deposition on ADP-activated HMEC-1 (by calculating HMEC-1 area covered by C5b-9 staining in pixel2) after 4-hr incubation with serum (diluted 1:2 in test medium) from case 7 taken during the acute phase before start of eculizumab treatment (pre-Ecu) and in full remission (normal renal and hematologic parameters) after eculizumab (at the adult dose of 1200 mg every 2 and 3 weeks; post-Ecu). Red arrows indicate times of sampling for plasma SC5b-9 and serum-induced ex vivo complement deposits. Green arrow: from this time, the patient was treated with eculizumab every 3 weeks. Data are mean ± SE of 15 fields examined for each sample. The horizontal rectangle shows range of endothelial C5b-9 deposits with control sera (mean ± SE). °P < .001 vs control serum; $P < .001 vs case 7 pre-Ecu. Marina Noris et al. Blood 2014;124:1715-1726 ©2014 by American Society of Hematology